A man takes an opioid for chronic pain, an SSRI for the depression that followed, and a statin for the cholesterol his sedentary, pain-limited life produced. Each drug was prescribed in isolation. Each has evidence linking it to testosterone suppression. No one checked whether the combination would suppress his HPG axis more than any single drug alone — because no study on that combination exists.
This scenario is not hypothetical. It describes millions of men.
A 2025 pharmacovigilance analysis of the FDA's Adverse Event Reporting System (FAERS) identified 42 drugs across 10 classes with positive signals for male hypogonadism (Xi et al., Andrology 2025). Twenty of those drugs did not mention hypogonadism on their labels. Three of the unlabeled drugs were classified as high risk. A complementary 2026 analysis using both FAERS and EudraVigilance identified 19 high-risk drugs for male infertility (Gong et al., Frontiers in Pharmacology 2026).
This article maps the pharmacological landscape — not as a list of drugs, but as a map of mechanisms. Where each drug hits the HPG axis determines what happens, how bad it gets, and what can be done about it.
The Pharmacological Map
The HPG axis has three levels: hypothalamus (GnRH pulse generator), pituitary (LH/FSH secretion), and gonad (testosterone production). Drugs can disrupt any level — or multiple levels simultaneously. Understanding where a drug hits determines the clinical picture and the treatment strategy.
Mechanism 1: Direct GnRH Suppression
The drugs: Opioids, glucocorticoids, cannabis (chronic heavy use)
These drugs directly suppress GnRH release from the hypothalamus, cutting off the signal at the source.
Opioids are the most studied. Mu, delta, and kappa receptor activation in the hypothalamus inhibits pulsatile GnRH secretion. Testosterone drops >50% within hours of opioid administration and remains suppressed for the duration of use. Prevalence of opioid-induced hypogonadism ranges from 21-86% depending on the population, with fewer than 10% ever diagnosed. The effect occurs regardless of opioid type, route, structure, or lipophilicity — but partial agonists like buprenorphine cause significantly less suppression (28% vs 65% hypogonadism prevalence compared to methadone; Hallinan 2009).
Glucocorticoids hit the axis at two levels. Centrally, they suppress GnRH and LH secretion. Peripherally, they directly impair Leydig cell steroidogenesis — dexamethasone at 10⁻⁷M produces a 60% decrease in cAMP and 80% decrease in androstenedione in cultured Leydig cells. Chronic oral prednisolone produces 33% lower testosterone versus controls. In one study, 14 of 16 men on chronic glucocorticoids had mean testosterone of 211 ng/dL versus 449 ng/dL in controls. Oral dexamethasone carries a 7.5-fold increased risk of hypogonadism. Inhaled glucocorticoids appear safe. The effect is reversible upon discontinuation.
Chronic heavy cannabis use suppresses GnRH through CB1 receptor activation in the hypothalamus. THC reduces testosterone by 65% in rhesus monkeys — an effect reversed by GnRH administration, confirming the central mechanism. A CB1 agonist completely blocked pulsatile GnRH release in GT1 cells. A 2025 claims-based study of 30,964 cannabis abuse/dependence patients found increased risk of erectile dysfunction, PDE5 inhibitor use, and testosterone deficiency (Davis et al., J Sex Med 2025). A 2026 study found that both THC and CBD directly inhibit androgen biosynthesis in steroidogenic cells, with CBD specifically reducing CYP17A1 activity (Rossier, BBRC 2026). The relationship is dose-dependent — occasional use may not be clinically significant, but chronic heavy use is a genuine HPG suppressor.
Mechanism 2: Prolactin-Mediated GnRH Suppression
The drugs: Antipsychotics, metoclopramide
These drugs block dopamine D2 receptors, removing the tonic inhibition of prolactin release. Elevated prolactin then suppresses kisspeptin neurons in the arcuate nucleus, shutting down pulsatile GnRH.
Antipsychotics are the most potent prolactin elevators. Hyperprolactinemia occurs in 18-72% of men on antipsychotics, with risperidone the worst offender at 70-100%. A dose-response meta-analysis of 165 studies (CNS Drugs, Aug 2025) confirmed that asenapine, haloperidol, iloperidone, lurasidone, olanzapine, paliperidone, risperidone, and ziprasidone all show dose-dependent prolactin rises. The notable exception: aripiprazole lowers prolactin at higher doses (inverse dose-response). Brexpiprazole, cariprazine, lumateperone, and quetiapine carry negligible prolactin risk.
But prolactin-mediated testosterone suppression is not the whole story. A prospective cohort study (n=135, Int J Psych Clin Pract, Nov 2025) found that switching to a prolactin-sparing antipsychotic reduced prolactin by ~68 ng/mL — but sexual dysfunction was not fully resolved. Additional mechanisms beyond the prolactin-HPG pathway contribute, likely including direct dopaminergic effects on reward and arousal circuits.
In drug-naive first-episode schizophrenia patients (n=189), males had higher prevalence of abnormal prolactin than females (32.3% vs 8.6%), and the relationship between prolactin and sex hormones differed depending on prolactin level — suggesting the regulatory interaction is more complex than a simple linear suppression (IJNP, 2025).
Mechanism 3: RFRP/GnIH Upregulation — The HPG Brake
The drugs: SSRIs
This is the most mechanistically distinctive pathway. SSRIs do not suppress the HPG accelerator (kisspeptin) — they activate the HPG brake.
Chronic citalopram treatment in animal models did not affect kisspeptin or GnRH expression. Instead, it increased RFRP (mammalian GnIH — gonadotropin-inhibitory hormone) neuronal numbers in the dorsomedial hypothalamus and RFRP fiber projections to the preoptic area. Eleven serotonin receptor types were identified on RFRP neurons — direct serotonergic modulation of the inhibitory pathway (Soga et al., Neuropharmacology 2010).
This is distinct from every other drug-induced HPG suppression mechanism. Opioids remove the accelerator. Antipsychotics raise the barrier. SSRIs step on the brake.
The clinical evidence is stronger than commonly acknowledged. In 86 SSRI-treated men with sexual dysfunction and 62 without, both groups had significantly lower LH, FSH, and testosterone versus healthy controls. Both groups showed diminished LH/FSH response to GnRH stimulation. 79.1% of the sexual dysfunction group and 43.5% of the non-dysfunction group had elevated prolactin (J Clin Psychopharmacol, 2008). Even men on SSRIs without sexual complaints showed suppressed HPG function.
All six major SSRIs decrease testosterone in H295R steroidogenic cells at clinically relevant concentrations. Multiple mechanisms converge: serotonin → GnRH suppression, prolactin elevation via dopamine interference, CYP17 inhibition, and aromatase upregulation.
The vicious cycle is clinically important: depression itself lowers testosterone (functional hypogonadism). SSRIs are prescribed for the depression. SSRIs further suppress the HPG axis via RFRP upregulation + prolactin elevation + direct steroidogenic inhibition. The resulting hypogonadal symptoms — fatigue, low libido, cognitive fog — worsen the depression, leading to dose escalation. Bupropion and mirtazapine have less HPG impact and may be preferable in men at risk.
Post-SSRI sexual dysfunction (PSSD) — persistent sexual and neurological symptoms after SSRI discontinuation — was formally acknowledged by the EMA in 2019 and added to SNOMED CT in 2024. The proposed mechanism involves persistent epigenetic changes: 626 gene promoters were epigenetically altered after 30-day citalopram exposure in one cell study (Kanhekar). This connects to the fragile axis concept — men with reduced KNDy neuron buffer may be more susceptible to persistent SSRI-induced damage.
Mechanism 4: Direct Gonadal Toxicity
The drugs: Chemotherapy agents, alcohol (chronic heavy use), anabolic steroids
These drugs damage the testes directly — Leydig cells, Sertoli cells, or both.
Chemotherapy (alkylating agents, platinum-based drugs) causes direct cytotoxic damage to gonadal tissue. Recovery depends on the agent, dose, and duration. Some damage is permanent.
Chronic heavy alcohol use is unique because it hits all three HPG levels simultaneously. Centrally, ethanol suppresses GnRH mRNA and elevates beta-endorphin. At the gonad, it inhibits 3β-HSD and 17-KSR enzymes, suppresses StAR via reactive oxygen species, and causes direct Leydig cell toxicity through acetaldehyde. Peripherally, it induces aromatase (increasing estrogen) and raises SHBG. A 2024 meta-analysis of 21 studies and 10,199 subjects found total testosterone decreased by 4.02 nmol/L, free testosterone by 0.17 nmol/L, while estradiol increased by 7.65 pg/mL — effects significant only in chronic drinkers (Santi et al., Andrology 2024). Prevalence: 50-75% of men with alcohol use disorder are hypogonadal. The damage threshold is approximately 80g/day. Alcohol is the only common substance that causes both primary and secondary hypogonadism.
Anabolic steroids cause HPG axis shutdown through negative feedback, as covered in The Price of Shortcuts. The Leydig cell damage revealed by INSL3 measurements persists even when testosterone levels normalize.
Mechanism 5: The SHBG Trap and Metabolic Interference
The drugs: Enzyme-inducing anticonvulsants, statins
Enzyme-inducing anticonvulsants (phenytoin, carbamazepine, phenobarbital) increase SHBG through hepatic CYP induction. This binds more circulating testosterone, lowering free testosterone while total testosterone may appear normal. It is a diagnostic trap — the standard total testosterone test looks fine while the man is effectively hypogonadal. Valproate acts differently: direct Leydig cell toxicity with 50% testosterone reduction in hCG-stimulated cells, plus central effects (decreased LH, FSH, increased prolactin). However, a large 2025 retrospective (n=91,917, Nature Communications) found no significant difference in infertility or testicular hypofunction in valproate-exposed men — animal concerns may not translate fully to clinical practice. Levetiracetam appears safer for reproductive function.
Statins reduce cholesterol — the substrate for steroidogenesis. A 2024 meta-analysis of 21 articles and 9,879 patients found RCTs showed −13.12 ng/dL testosterone reduction (p=0.03), while cross-sectional studies showed −55 ng/dL (p<0.00001). Atorvastatin specifically reduced total testosterone (11.4 vs 13.4 nmol/L, p=0.006) in a dose-response pattern. I classify statins as amplifiers, not drivers — subclinical in isolation but potentially meaningful in borderline men or when stacked with other HPG suppressors.
Mechanism 6: Neurosteroid Disruption
The drugs: 5α-reductase inhibitors (finasteride, dutasteride)
These drugs don't cause hypogonadism in the classical sense — testosterone actually rises slightly. But they deplete allopregnanolone, a critical neurosteroid GABA-A modulator, causing mood disturbance and depression. A 2025 meta-analysis of five studies covering 2.5 million patients found a hazard ratio of 1.31 for depression (medRxiv). The EMA launched a specific safety probe in 2024 regarding suicidality risk.
Post-finasteride syndrome — persistent sexual, neurological, and psychological symptoms after discontinuation — parallels PSSD in its proposed epigenetic mechanism. Finasteride also satisfied both dechallenge and rechallenge criteria for male infertility in the Gong 2026 pharmacovigilance analysis — the strongest causality evidence of any drug studied.
These drugs belong in this map not because they suppress testosterone, but because they disrupt the downstream steroid cascade in ways that produce hypogonadism-like symptoms.
Mechanism 7: Intentional HPG Shutdown
The drugs: GnRH agonists (leuprolide, goserelin, triptorelin)
These represent the extreme end of the spectrum — intentional castration-level testosterone suppression for prostate cancer (androgen deprivation therapy). They achieve 95% testosterone suppression by desensitizing pituitary GnRH receptors. Side effects include bone fractures, cognitive decline, metabolic syndrome, and increased cardiovascular risk. A meta-analysis found higher cardiovascular events with GnRH agonists versus antagonists.
While not "accidental," ADT demonstrates what happens at the far end of drug-induced HPG suppression — and many of its consequences (bone loss, metabolic syndrome, cognitive impairment) occur subclinically in men on less potent suppressors.
The Surprising Exceptions
GLP-1 receptor agonists are protective, not harmful. A FAERS analysis found a reporting odds ratio for erectile dysfunction of 0.41 — below expected, indicating a protective signal. This aligns with what we've covered in the obesity article: GLP-1 RAs restore HPG axis function by addressing the metabolic driver of functional hypogonadism. An ICS-EUS 2025 systematic review confirmed significant testosterone increases and improved semen quality in obese men.
Metformin is context-dependent. In men with metabolic syndrome and lifestyle changes, it may help restore testosterone and improve LH pulsatility. In men with type 2 diabetes on insulin, it may reduce testosterone. A 2025 study found negative effects on free testosterone after 30 days. It is not a straightforward stealer — its effect depends on the metabolic context.
The Polypharmacy Crisis
This is the thesis of this article, and it is both obvious and unstudied.
A man on an opioid (Mechanism 1: GnRH suppression) plus an antipsychotic (Mechanism 2: prolactin-mediated suppression) plus an SSRI (Mechanism 3: RFRP/GnIH brake activation) is being hit at three distinct mechanistic levels of the same axis simultaneously. There is no reason to expect the effects are simply additive — they may be synergistic, because the axis has been attacked at every regulatory checkpoint.
Yet no study has examined HPG interactions between multiple drug classes. No drug interaction database includes hormonal axis effects. No guideline addresses polypharmacy stacking on the HPG axis.
The Xi 2025 FAERS analysis proved that 20 out of 42 drugs with positive hypogonadism signals don't mention it on their labels. The Gong 2026 analysis cross-validated infertility signals across two independent databases. The EAU 2025 guidelines (Salonia et al., European Urology, May 2025) emphasize detailed medication history review and recommend eliminating drugs that interfere with the HPG axis before starting TRT — but provide no specific polypharmacy screening protocol.
The BSSM explicitly recommends testosterone screening for long-term opiates, anticonvulsants, and antipsychotics. The Endocrine Society mentions opioids and high-dose glucocorticoids. No guideline recommends screening for SSRIs, statins, PPIs, alcohol, cannabis, or polypharmacy combinations.
The gap is not in what we know about individual drugs. It is in what we have never asked about their combinations.
What This Means for Patients
If you are on one or more of the drugs discussed here and experiencing symptoms consistent with low testosterone — fatigue, low libido, depressed mood, cognitive fog, reduced muscle mass — ask for a morning fasting total and free testosterone level. If it's low, ask whether your medication could be contributing.
The reversibility data is encouraging. Opioid-induced hypogonadism resolves days to weeks after dose reduction or discontinuation. Glucocorticoid effects reverse when the drug stops. Antipsychotic-induced hyperprolactinemia responds to switching agents or adding aripiprazole. SSRI effects are more complex but potentially reversible.
But "just stop the drug" is not always possible. The opioid was prescribed for real pain. The antipsychotic manages real psychosis. The SSRI treats real depression. In these cases, knowing where each drug hits the axis informs the treatment strategy:
- For hypothalamic-level suppression (opioids, glucocorticoids): SERMs like enclomiphene can potentially work by stimulating the pituitary below the block
- For prolactin-mediated suppression (antipsychotics): dopamine agonists or agent switching
- For gonadal-level damage (chemotherapy, chronic alcohol): direct testosterone replacement may be necessary
- For SHBG traps (anticonvulsants): measure free testosterone, not just total
The most important intervention is the simplest: a medication review that considers hormonal effects. Before starting TRT for low testosterone, ask whether any of the patient's current medications could be causing it.
The Bottom Line
At least 42 drugs across 16 classes can suppress male testosterone through seven distinct mechanisms — from direct GnRH suppression to neurosteroid disruption. Twenty lack label warnings. The most dangerous scenario is not any single drug but the stacking of multiple HPG suppressors in the same man — a situation that is common in clinical practice and absent from clinical research.
The pharmacological map of HPG disruption is now clear. What is missing is the study that puts the drugs together — because that is how they exist in patients.